At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LGVN Longeveron Inc
Post-Mkt 10-30 17:11:25 EDT
1.67
-0.08
-4.57%
盘后1.67
+0.000.00%
16:00 EDT
High1.80Low1.58Vol80.74K
Open1.78D1 Closing1.75Amplitude12.51%
Mkt Cap5.28MTradable Cap4.55MTotal Shares3.16M
T/O139.13KT/O Rate2.96%Tradable Shares2.73M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Longeveron Announces Engagement of Lucid Capital Markets
THOMSON REUTERS  ·  10-28 21:15
Longeveron Announces Engagement of Lucid Capital Markets
Longeveron - Retains Lucid Capital Markets to Explore Strategic Opportunities Including Business Combination
THOMSON REUTERS  ·  10-28 21:15
Longeveron - Retains Lucid Capital Markets to Explore Strategic Opportunities Including Business Combination
Longeveron Highlights Positive HLHS Trial Safety Findings
TIPRANKS  ·  10-27
Longeveron Highlights Positive HLHS Trial Safety Findings
Longeveron reports ELPIS II trial misses primary endpoint
TIPRANKS  ·  10-26
Longeveron reports ELPIS II trial misses primary endpoint
Longeveron’s Laromestrocel Shows Fewer Major Adverse Cardiac Events in Phase 2b Trial
Reuters  ·  10-26
Longeveron’s Laromestrocel Shows Fewer Major Adverse Cardiac Events in Phase 2b Trial
Longeveron Announces Updated Results from Elpis Ii Phase 2B Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (Hlhs)
THOMSON REUTERS  ·  10-26
Longeveron Announces Updated Results from Elpis Ii Phase 2B Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (Hlhs)
Longeveron Announces Chief Medical Officer Leadership Transition
TIPRANKS  ·  10-15
Longeveron Announces Chief Medical Officer Leadership Transition
Longeveron Chief Medical Officer Nataliya Agafonova Steps Down Effective October 14, 2026
Reuters  ·  10-15
Longeveron Chief Medical Officer Nataliya Agafonova Steps Down Effective October 14, 2026
Longeveron Says Phase 2b Trial Shows Laromestrocel Improves Physical Condition in Age-Related Frailty Patients
Reuters  ·  10-01
Longeveron Says Phase 2b Trial Shows Laromestrocel Improves Physical Condition in Age-Related Frailty Patients
Longeveron to Participate in Three Longevity/Aging Investment Conferences
GlobeNewswire  ·  10-01
Longeveron to Participate in Three Longevity/Aging Investment Conferences
Longeveron Says ELPIS II Phase 2b Trial of Laromestrocel in HLHS Misses Primary Endpoint at 12 Months
Reuters  ·  09-24
Longeveron Says ELPIS II Phase 2b Trial of Laromestrocel in HLHS Misses Primary Endpoint at 12 Months
Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Longeveron (LGVN)
TIPRANKS  ·  09-21
Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Longeveron (LGVN)
Top Midday Decliners
MT Newswires Live  ·  09-18
Top Midday Decliners
Longeveron Stock (LGVN) Plummets 56% on a Failed Clinical Trial
TIPRANKS  ·  09-18
Longeveron Stock (LGVN) Plummets 56% on a Failed Clinical Trial
Stocks to Watch: Generac, Vicor, Longeveron, Viant
Dow Jones  ·  09-17
Stocks to Watch: Generac, Vicor, Longeveron, Viant
Longeveron Explores Strategic Options After Therapy Fails Mid-Stage Trial for Infant Heart Condition
Reuters  ·  09-17
Longeveron Explores Strategic Options After Therapy Fails Mid-Stage Trial for Infant Heart Condition
Longeveron Exploring Options to Maximize Shareholder Value After Heart Disease Drug Misses Endpoint
Dow Jones  ·  09-17
Longeveron Exploring Options to Maximize Shareholder Value After Heart Disease Drug Misses Endpoint
Longeveron Says ELPIS II Trial of Laromestrocel in Hypoplastic Left Heart Syndrome Misses Primary Endpoint
Reuters  ·  09-17
Longeveron Says ELPIS II Trial of Laromestrocel in Hypoplastic Left Heart Syndrome Misses Primary Endpoint
Longeveron to resume trading at 5:55 pm ET
TIPRANKS  ·  09-17
Longeveron to resume trading at 5:55 pm ET
Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial
TIPRANKS  ·  09-17
Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial

Introduction

Company Name.
Longeveron Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Issue price:
--